Frontiers in Cardiovascular Medicine
Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease
ReviewInterventions
- FGF21 analogues
- GLP-1 receptor agonists
- PPAR signalling
- Metabolic dysfunction-associated steatotic liver disease
- Coronary artery disease
- Humans
The paper
Second Affiliated Hospital of Zhejiang University
Frontiers in Cardiovascular Medicine, 27 Jul 2026
